610 related articles for article (PubMed ID: 20479194)
1. Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.
Chen F; Zhao Y; Liu M; Li D; Wu H; Chen H; Zhu Y; Luo F; Zhong J; Zhou Y; Qi Z; Zhang XL
Antimicrob Agents Chemother; 2010 Aug; 54(8):3355-64. PubMed ID: 20479194
[TBL] [Abstract][Full Text] [Related]
2. Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library.
Lü X; Yao M; Zhang JM; Yang J; Lei YF; Huang XJ; Jia ZS; Ma L; Lan HY; Xu ZK; Yin W
Int J Mol Med; 2014 May; 33(5):1312-8. PubMed ID: 24573486
[TBL] [Abstract][Full Text] [Related]
3. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2.
Chen F; Hu Y; Li D; Chen H; Zhang XL
PLoS One; 2009 Dec; 4(12):e8142. PubMed ID: 19997645
[TBL] [Abstract][Full Text] [Related]
4. Selection of peptides binding to HCV e2 and inhibiting viral infectivity.
Hong HW; Lee SW; Myung H
J Microbiol Biotechnol; 2010 Dec; 20(12):1769-71. PubMed ID: 21193836
[TBL] [Abstract][Full Text] [Related]
5. Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81.
Liu X; Chen N; Lin S; Liu M
Int J Mol Med; 2016 Mar; 37(3):836-42. PubMed ID: 26796693
[TBL] [Abstract][Full Text] [Related]
6. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.
Yin P; Zhang L; Ye F; Deng Y; Lu S; Li YP; Zhang L; Tan W
Sci Rep; 2017 Jun; 7(1):3976. PubMed ID: 28638089
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
[TBL] [Abstract][Full Text] [Related]
8. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes.
Abe K; Nozaki A; Tamura K; Ikeda M; Naka K; Dansako H; Hoshino HO; Tanaka K; Kato N
Microbiol Immunol; 2007; 51(1):117-25. PubMed ID: 17237607
[TBL] [Abstract][Full Text] [Related]
9. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
10. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.
Liu S; McCormick KD; Zhao W; Zhao T; Fan D; Wang T
Hepatology; 2012 Aug; 56(2):484-91. PubMed ID: 22334503
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
[TBL] [Abstract][Full Text] [Related]
12. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.
Helle F; Wychowski C; Vu-Dac N; Gustafson KR; Voisset C; Dubuisson J
J Biol Chem; 2006 Sep; 281(35):25177-83. PubMed ID: 16809348
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein.
Yang D; Meng X; Yu Q; Xu L; Long Y; Liu B; Fang X; Zhu H
Antimicrob Agents Chemother; 2013 Oct; 57(10):4937-44. PubMed ID: 23877701
[TBL] [Abstract][Full Text] [Related]
14. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein.
Nozaki A; Ikeda M; Naganuma A; Nakamura T; Inudoh M; Tanaka K; Kato N
J Biol Chem; 2003 Mar; 278(12):10162-73. PubMed ID: 12522210
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
Yokokawa H; Shinohara M; Teraoka Y; Imamura M; Nakamura N; Watanabe N; Date T; Aizaki H; Iwamura T; Narumi H; Chayama K; Wakita T
PLoS One; 2022; 17(9):e0274283. PubMed ID: 36137152
[TBL] [Abstract][Full Text] [Related]
16. Specific ligands for classical swine fever virus screened from landscape phage display library.
Yin L; Luo Y; Liang B; Wang F; Du M; Petrenko VA; Qiu HJ; Liu A
Antiviral Res; 2014 Sep; 109():68-71. PubMed ID: 24977927
[TBL] [Abstract][Full Text] [Related]
17. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.
Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R
Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485
[TBL] [Abstract][Full Text] [Related]
18. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
[TBL] [Abstract][Full Text] [Related]
19. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
20. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
